Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial.

Jones RB, Hiemstra TF, Ballarin J, Blockmans DE, Brogan P, Bruchfeld A, Cid MC, Dahlsveen K, de Zoysa J, Espigol-Frigolé G, Lanyon P, Peh CA, Tesar V, Vaglio A, Walsh M, Walsh D, Walters G, Harper L, Jayne D; European Vasculitis Study Group (EUVAS).

Ann Rheum Dis. 2019 Mar;78(3):399-405. doi: 10.1136/annrheumdis-2018-214245. Epub 2019 Jan 5.

PMID:
30612116
2.

Expression and Function of IL12/23 Related Cytokine Subunits (p35, p40, and p19) in Giant-Cell Arteritis Lesions: Contribution of p40 to Th1- and Th17-Mediated Inflammatory Pathways.

Espígol-Frigolé G, Planas-Rigol E, Lozano E, Corbera-Bellalta M, Terrades-García N, Prieto-González S, García-Martínez A, Hernández-Rodríguez J, Grau JM, Cid MC.

Front Immunol. 2018 Apr 20;9:809. doi: 10.3389/fimmu.2018.00809. eCollection 2018.

3.

Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients.

Prieto-González S, Terrades-García N, Corbera-Bellalta M, Planas-Rigol E, Miyabe C, Alba MA, Ponce A, Tavera-Bahillo I, Murgia G, Espígol-Frigolé G, Marco-Hernández J, Hernández-Rodríguez J, García-Martínez A, Unizony SH, Cid MC.

RMD Open. 2017 Dec 22;3(2):e000570. doi: 10.1136/rmdopen-2017-000570. eCollection 2017.

4.

Biological treatments in giant cell arteritis & Takayasu arteritis.

Samson M, Espígol-Frigolé G, Terrades-García N, Prieto-González S, Corbera-Bellalta M, Alba-Rovira R, Hernández-Rodríguez J, Audia S, Bonnotte B, Cid MC.

Eur J Intern Med. 2018 Apr;50:12-19. doi: 10.1016/j.ejim.2017.11.003. Epub 2017 Nov 13. Review.

PMID:
29146018
5.

Endothelin-1 promotes vascular smooth muscle cell migration across the artery wall: a mechanism contributing to vascular remodelling and intimal hyperplasia in giant-cell arteritis.

Planas-Rigol E, Terrades-Garcia N, Corbera-Bellalta M, Lozano E, Alba MA, Segarra M, Espígol-Frigolé G, Prieto-González S, Hernández-Rodríguez J, Preciado S, Lavilla R, Cid MC.

Ann Rheum Dis. 2017 Sep;76(9):1624-1634. doi: 10.1136/annrheumdis-2016-210792. Epub 2017 Jun 12.

6.

The Expanding Role of Imaging in Systemic Vasculitis.

Prieto-González S, Espígol-Frigolé G, García-Martínez A, Alba MA, Tavera-Bahillo I, Hernández-Rodríguez J, Renú A, Gilabert R, Lomeña F, Cid MC.

Rheum Dis Clin North Am. 2016 Nov;42(4):733-751. doi: 10.1016/j.rdc.2016.07.009. Epub 2016 Sep 7. Review.

PMID:
27742024
7.

Identification of IL-23p19 as an endothelial proinflammatory peptide that promotes gp130-STAT3 signaling.

Espígol-Frigolé G, Planas-Rigol E, Ohnuki H, Salvucci O, Kwak H, Ravichandran S, Luke B, Cid MC, Tosato G.

Sci Signal. 2016 Mar 15;9(419):ra28. doi: 10.1126/scisignal.aad2357.

8.

Description and Validation of Histological Patterns and Proposal of a Dynamic Model of Inflammatory Infiltration in Giant-cell Arteritis.

Hernández-Rodríguez J, Murgia G, Villar I, Campo E, Mackie SL, Chakrabarty A, Hensor EM, Morgan AW, Font C, Prieto-González S, Espígol-Frigolé G, Grau JM, Cid MC.

Medicine (Baltimore). 2016 Feb;95(8):e2368. doi: 10.1097/MD.0000000000002368.

9.

Blocking interferon γ reduces expression of chemokines CXCL9, CXCL10 and CXCL11 and decreases macrophage infiltration in ex vivo cultured arteries from patients with giant cell arteritis.

Corbera-Bellalta M, Planas-Rigol E, Lozano E, Terrades-García N, Alba MA, Prieto-González S, García-Martínez A, Albero R, Enjuanes A, Espígol-Frigolé G, Hernández-Rodríguez J, Roux-Lombard P, Ferlin WG, Dayer JM, Kosco-Vilbois MH, Cid MC.

Ann Rheum Dis. 2016 Jun;75(6):1177-86. doi: 10.1136/annrheumdis-2015-208371. Epub 2015 Dec 23.

10.

Clinical and genetic characterization of the autoinflammatory diseases diagnosed in an adult reference center.

Hernández-Rodríguez J, Ruíz-Ortiz E, Tomé A, Espinosa G, González-Roca E, Mensa-Vilaró A, Prieto-González S, Espígol-Frigolé G, Mensa J, Cardellach F, Grau JM, Cid MC, Yagüe J, Aróstegui JI, Cervera R.

Autoimmun Rev. 2016 Jan;15(1):9-15. doi: 10.1016/j.autrev.2015.08.008. Epub 2015 Aug 21. Review.

PMID:
26299986
11.

Evaluation of aortic inflammation using computed tomographic angiography: vasculitis, atherosclerosis, or both.

Prieto-González S, Arguis P, Alba MA, García-Martínez A, Espígol-Frigolé G, Grau JM, Hernández-Rodríguez J, Cid MC.

J Am Geriatr Soc. 2015 Feb;63(2):415-6. doi: 10.1111/jgs.13272. No abstract available.

PMID:
25688629
12.

Effect of glucocorticoid treatment on computed tomography angiography detected large-vessel inflammation in giant-cell arteritis. A prospective, longitudinal study.

Prieto-González S, García-Martínez A, Tavera-Bahillo I, Hernández-Rodríguez J, Gutiérrez-Chacoff J, Alba MA, Murgia G, Espígol-Frigolé G, Sánchez M, Arguis P, Cid MC.

Medicine (Baltimore). 2015 Feb;94(5):e486. doi: 10.1097/MD.0000000000000486.

13.

Advances in the diagnosis of large vessel vasculitis.

Espígol-Frigolé G, Prieto-González S, Alba MA, Tavera-Bahillo I, García-Martínez A, Gilabert R, Hernández-Rodríguez J, Cid MC.

Rheum Dis Clin North Am. 2015;41(1):125-40, ix. doi: 10.1016/j.rdc.2014.10.001. Review.

PMID:
25399944
14.

Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients.

Alba MA, García-Martínez A, Prieto-González S, Tavera-Bahillo I, Corbera-Bellalta M, Planas-Rigol E, Espígol-Frigolé G, Butjosa M, Hernández-Rodríguez J, Cid MC.

Medicine (Baltimore). 2014 Jul;93(5):194-201. doi: 10.1097/MD.0000000000000033.

15.

Authors' response to the eLetter by Moiseev et al.

Prieto-González S, Depetris M, García-Martínez A, Espígol-Frigolé G, Tavera-Bahillo I, Corbera-Bellalta M, Planas-Rigol E, Alba MA, Hernández-Rodríguez J, Grau JM, Lomeña F, Cid MC.

Ann Rheum Dis. 2014 Nov;73(11):e71. doi: 10.1136/annrheumdis-2014-206231. Epub 2014 Aug 8. No abstract available.

PMID:
25107561
16.

Positron emission tomography assessment of large vessel inflammation in patients with newly diagnosed, biopsy-proven giant cell arteritis: a prospective, case-control study.

Prieto-González S, Depetris M, García-Martínez A, Espígol-Frigolé G, Tavera-Bahillo I, Corbera-Bellata M, Planas-Rigol E, Alba MA, Hernández-Rodríguez J, Grau JM, Lomeña F, Cid MC.

Ann Rheum Dis. 2014 Jul;73(7):1388-92. doi: 10.1136/annrheumdis-2013-204572. Epub 2014 Mar 24.

17.

Treatment with angiotensin II receptor blockers is associated with prolonged relapse-free survival, lower relapse rate, and corticosteroid-sparing effect in patients with giant cell arteritis.

Alba MA, García-Martínez A, Prieto-González S, Espígol-Frigolé G, Butjosa M, Tavera-Bahillo I, Rodríguez-Pintó I, Hernández-Rodríguez J, Cid MC.

Semin Arthritis Rheum. 2014 Jun;43(6):772-7. doi: 10.1016/j.semarthrit.2013.10.009. Epub 2013 Oct 30.

PMID:
24315461
18.

Prospective long term follow-up of a cohort of patients with giant cell arteritis screened for aortic structural damage (aneurysm or dilatation).

García-Martínez A, Arguis P, Prieto-González S, Espígol-Frigolé G, Alba MA, Butjosa M, Tavera-Bahillo I, Hernández-Rodríguez J, Cid MC.

Ann Rheum Dis. 2014 Oct;73(10):1826-32. doi: 10.1136/annrheumdis-2013-203322. Epub 2013 Jul 19.

PMID:
23873881
19.

Changes in biomarkers after therapeutic intervention in temporal arteries cultured in Matrigel: a new model for preclinical studies in giant-cell arteritis.

Corbera-Bellalta M, García-Martínez A, Lozano E, Planas-Rigol E, Tavera-Bahillo I, Alba MA, Prieto-González S, Butjosa M, Espígol-Frigolé G, Hernández-Rodríguez J, Fernández PL, Roux-Lombard P, Dayer JM, Rahman MU, Cid MC.

Ann Rheum Dis. 2014 Mar;73(3):616-23. doi: 10.1136/annrheumdis-2012-202883. Epub 2013 Apr 27.

PMID:
23625984
20.

Functionally relevant treg cells are present in giant cell arteritis lesions: comment on the article by Samson et al.

Corbera-Bellalta M, Planas-Rigol E, Espígol-Frigolé G, Lozano E, Cid MC.

Arthritis Rheum. 2013 Apr;65(4):1133-4. doi: 10.1002/art.37865. No abstract available.

21.

Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis.

Espígol-Frigolé G, Corbera-Bellalta M, Planas-Rigol E, Lozano E, Segarra M, García-Martínez A, Prieto-González S, Hernández-Rodríguez J, Grau JM, Rahman MU, Cid MC.

Ann Rheum Dis. 2013 Sep 1;72(9):1481-7. doi: 10.1136/annrheumdis-2012-201836. Epub 2012 Sep 19.

PMID:
22993227
22.

A20/TNFAIP3 inhibits NF-κB activation induced by the Kaposi's sarcoma-associated herpesvirus vFLIP oncoprotein.

Sakakibara S, Espigol-Frigole G, Gasperini P, Uldrick TS, Yarchoan R, Tosato G.

Oncogene. 2013 Mar 7;32(10):1223-32. doi: 10.1038/onc.2012.145. Epub 2012 Apr 23.

23.

Patient-reported outcomes in polymyalgia rheumatica.

Matteson EL, Maradit-Kremers H, Cimmino MA, Schmidt WA, Schirmer M, Salvarani C, Bachta A, Dejaco C, Duftner C, Slott Jensen H, Poór G, Kaposi NP, Mandl P, Balint PV, Schmidt Z, Iagnocco A, Cantini F, Nannini C, Macchioni P, Pipitone N, Del Amo M, Espígol-Frigolé G, Cid MC, Martínez-Taboada VM, Nordborg E, Direskeneli H, Aydin SZ, Ahmed K, Hazelman B, Pease C, Wakefield RJ, Luqmani R, Abril A, Marcus R, Gonter NJ, Maz M, Crowson CS, Dasgupta B.

J Rheumatol. 2012 Apr;39(4):795-803. doi: 10.3899/jrheum.110977. Epub 2012 Mar 15.

24.

2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative.

Dasgupta B, Cimmino MA, Kremers HM, Schmidt WA, Schirmer M, Salvarani C, Bachta A, Dejaco C, Duftner C, Jensen HS, Duhaut P, Poór G, Kaposi NP, Mandl P, Balint PV, Schmidt Z, Iagnocco A, Nannini C, Cantini F, Macchioni P, Pipitone N, Del Amo M, Espígol-Frigolé G, Cid MC, Martínez-Taboada VM, Nordborg E, Direskeneli H, Aydin SZ, Ahmed K, Hazleman B, Silverman B, Pease C, Wakefield RJ, Luqmani R, Abril A, Michet CJ, Marcus R, Gonter NJ, Maz M, Carter RE, Crowson CS, Matteson EL.

Arthritis Rheum. 2012 Apr;64(4):943-54. doi: 10.1002/art.34356.

25.

2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative.

Dasgupta B, Cimmino MA, Maradit-Kremers H, Schmidt WA, Schirmer M, Salvarani C, Bachta A, Dejaco C, Duftner C, Jensen HS, Duhaut P, Poór G, Kaposi NP, Mandl P, Balint PV, Schmidt Z, Iagnocco A, Nannini C, Cantini F, Macchioni P, Pipitone N, Amo MD, Espígol-Frigolé G, Cid MC, Martínez-Taboada VM, Nordborg E, Direskeneli H, Aydin SZ, Ahmed K, Hazleman B, Silverman B, Pease C, Wakefield RJ, Luqmani R, Abril A, Michet CJ, Marcus R, Gonter NJ, Maz M, Carter RE, Crowson CS, Matteson EL.

Ann Rheum Dis. 2012 Apr;71(4):484-92. doi: 10.1136/annrheumdis-2011-200329.

26.

Central nervous system vasculitis: still more questions than answers.

Alba MA, Espígol-Frigolé G, Prieto-González S, Tavera-Bahillo I, García-Martínez A, Butjosa M, Hernández-Rodríguez J, Cid MC.

Curr Neuropharmacol. 2011 Sep;9(3):437-48. doi: 10.2174/157015911796557920.

27.

MicroRNA126 contributes to granulocyte colony-stimulating factor-induced hematopoietic progenitor cell mobilization by reducing the expression of vascular cell adhesion molecule 1.

Salvucci O, Jiang K, Gasperini P, Maric D, Zhu J, Sakakibara S, Espigol-Frigole G, Wang S, Tosato G.

Haematologica. 2012 Jun;97(6):818-26. doi: 10.3324/haematol.2011.056945. Epub 2012 Jan 22.

28.

Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using CT angiography.

Prieto-González S, Arguis P, García-Martínez A, Espígol-Frigolé G, Tavera-Bahillo I, Butjosa M, Sánchez M, Hernández-Rodríguez J, Grau JM, Cid MC.

Ann Rheum Dis. 2012 Jul;71(7):1170-6. doi: 10.1136/annrheumdis-2011-200865. Epub 2012 Jan 20.

PMID:
22267328
29.

Kaposi sarcoma herpesvirus promotes endothelial-to-mesenchymal transition through Notch-dependent signaling.

Gasperini P, Espigol-Frigole G, McCormick PJ, Salvucci O, Maric D, Uldrick TS, Polizzotto MN, Yarchoan R, Tosato G.

Cancer Res. 2012 Mar 1;72(5):1157-69. doi: 10.1158/0008-5472.CAN-11-3067. Epub 2012 Jan 11.

30.

Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis--a prospective longitudinal study.

Visvanathan S, Rahman MU, Hoffman GS, Xu S, García-Martínez A, Segarra M, Lozano E, Espígol-Frigolé G, Hernández-Rodríguez J, Cid MC.

Rheumatology (Oxford). 2011 Nov;50(11):2061-70. doi: 10.1093/rheumatology/ker163. Epub 2011 Aug 25.

31.

Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor alpha and interleukin-6) in the long-term followup of patients with giant cell arteritis.

García-Martínez A, Hernández-Rodríguez J, Espígol-Frigolé G, Prieto-González S, Butjosa M, Segarra M, Lozano E, Cid MC.

Arthritis Care Res (Hoboken). 2010 Jun;62(6):835-41. doi: 10.1002/acr.20043.

32.

Treatment of polymyalgia rheumatica: a systematic review.

Hernández-Rodríguez J, Cid MC, López-Soto A, Espigol-Frigolé G, Bosch X.

Arch Intern Med. 2009 Nov 9;169(20):1839-50. doi: 10.1001/archinternmed.2009.352. Review.

PMID:
19901135
33.

Small-vessel vasculitis surrounding an uninflamed temporal artery as a diagnostic criterion for polymyalgia rheumatica: comment on the article by Chatelain et al.

Cid MC, Hernández-Rodríguez J, Espígol-Frigolé G, Butjosa M, Prieto-González S, García-Martínez A, Grau JM.

Arthritis Rheum. 2009 Sep;60(9):2853-4. doi: 10.1002/art.24756. No abstract available.

34.

The spectrum of vascular involvement in giant-cell arteritis: clinical consequences of detrimental vascular remodelling at different sites.

Cid MC, Prieto-González S, Arguis P, Espígol-Frigolé G, Butjosa M, Hernández-Rodríguez J, Segarra M, Lozano E, García-Martínez A.

APMIS Suppl. 2009 Jun;(127):10-20. doi: 10.1111/j.1600-0463.2009.02471.x. Review.

PMID:
19515134
35.

Increased expression of the endothelin system in arterial lesions from patients with giant-cell arteritis: association between elevated plasma endothelin levels and the development of ischaemic events.

Lozano E, Segarra M, Corbera-Bellalta M, García-Martínez A, Espígol-Frigolé G, Plà-Campo A, Hernández-Rodríguez J, Cid MC.

Ann Rheum Dis. 2010 Feb;69(2):434-42. doi: 10.1136/ard.2008.105692. Epub 2009 Mar 15.

PMID:
19289383
36.

New therapeutic targets in giant-cell arteritis. Considerations based on the current pathogenic model and the availability of new therapeutic agents.

Lozano E, Segarra M, García-Martínez A, Espígol-Frigolé G, Hernández-Rodríguez J, Cid MC.

Clin Exp Rheumatol. 2008 May-Jun;26(3 Suppl 49):S141-50. Review. No abstract available.

PMID:
18799072
37.

Five clinical conundrums in the management of giant cell arteritis.

Cid MC, García-Martínez A, Lozano E, Espígol-Frigolé G, Hernández-Rodríguez J.

Rheum Dis Clin North Am. 2007 Nov;33(4):819-34, vii. Review.

PMID:
18037119
38.

Development of ischemic complications in patients with giant cell arteritis presenting with apparently isolated polymyalgia rheumatica: study of a series of 100 patients.

Hernández-Rodríguez J, Font C, García-Martínez A, Espígol-Frigolé G, Sanmartí R, Cañete JD, Grau JM, Cid MC.

Medicine (Baltimore). 2007 Jul;86(4):233-41.

39.

Sustained spontaneous clinical remission in giant cell arteritis: report of two cases with long-term followup.

Hernández-Rodríguez J, García-Martínez A, Espígol-Frigolé G, Grau JM, Collado A, Cid MC.

Arthritis Rheum. 2006 Feb 15;55(1):160-2. No abstract available.

Supplemental Content

Loading ...
Support Center